Latest Press Releases
BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results
Includes data collected from six different leading US children’s hospitals over a twelve-month period.
August 31, 2021
BioPorto Initiates Patient Enrollment for US Pediatric Study of The NGAL Test™
First patients enrolled at Cincinnati Children’s Hospital, a leading US center for critical care nephrology.
June 23, 2020
Danish Team of Researchers to Test Treatment of Critically Ill Patients Suffering from COVID-19
The Innovation Fund Denmark has awarded DKK 3 million to test if the drug Iloprost can improve survival rates in SARS-Co-V2 infected patients in need of respiratory treatment.
May 14, 2020
BioPorto and the University of Southern Denmark in collaboration to fast track development of test to detect COVID-19 in less than 10 minutes
The inexpensive, reliable and effective point-of-care test is expected to be available in the 2nd half of 2020.
April 1, 2020
BioPorto to provide additional patient information in support of its US application for regulatory clearance of The NGAL Test™ for pediatric risk assessment of AKI
The Company expects to submit a revised and supplemented application in Q2 2020.
November 18, 2019
BioPorto submits answers to the FDA regarding The NGAL Test™ for risk assessment for AKI in pediatric patients
Response supplements the BioPorto application for pediatric use of The NGAL Test™ for risk assessment of acute kidney injury (AKI).
October 17, 2019
BioPorto Submits Pediatric Application to FDA for The NGAL Test™ Under Breakthrough Designation
First test focused on risk assessment of Acute Kidney Injury in pediatric patients.
May 15, 2019
BioPorto Appoints New President of BioPorto Diagnostics, Inc.
Company Plans to Bring Novel Kidney Diagnostic to US Market
April 15, 2019